Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THARROS study of budesonide + glycopyrronium + formoterol versus glycopyrronium + formoterol in COPD cardiopulmonary outcomes
CTR20242750Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of budesonide, glycopyrronium, formoterol in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Started Sep 2024; status: active.
02
Drugs
budesonideglycopyrroniumformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20242750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242750.